IMEXPHARM CORPORATION

IMEXPHARM CORPORATION: A Public-Listed Pillar of Vietnam’s Pharmaceutical Industry

Unlike HAEM VINA’s export-manufacturing profile, IMEXPHARM CORPORATION represents a mature, publicly listed pharmaceutical producer at the heart of Vietnam’s healthcare system. Operating under the Vietnamese name CÔNG TY CỔ PHẦN DƯỢC PHẨM IMEXPHARM, the company was established in 2001 and is listed on the Ho Chi Minh Stock Exchange (HOSE) under the ticker IMP.

IMEXPHARM’s business model is firmly rooted in the manufacture of pharmaceuticals, medicinal chemicals, and botanical products, supported by a nationwide distribution footprint and multiple regional branches. With over 1,450 employees, the company operates at an industrial scale that few domestic pharmaceutical firms can match.

Financially, IMEXPHARM shows consistent, disciplined growth rather than volatility. In FY2024, total assets increased to USD 102.9 million, while sales rose to USD 90.59 million, representing a 10.59% year-on-year increase. Profit after tax reached USD 13.18 million, continuing a multi-year upward trend, albeit at a more moderate pace (+7.11% YoY). Crucially, working capital stood at a very strong USD 44.69 million, underscoring excellent liquidity—an essential feature in a sector heavily influenced by regulatory compliance, inventory control, and long receivable cycles.

Ownership and governance further reinforce IMEXPHARM’s institutional profile. The company is chaired by Sung M. W., with day-to-day operations led by Tran T. D. (General Director). Its shareholder base combines foreign strategic capital—led by SK Investment Vina III Pte. Ltd. (47.69%)—with significant domestic institutional participation, including Vietnam Pharmaceutical Corporation. This hybrid ownership structure supports both governance discipline and long-term capital stability.

For investors, regulators, and healthcare partners, IMEXPHARM CORPORATION stands as a benchmark pharmaceutical manufacturer in Vietnam—characterized by strong capitalization, predictable earnings growth, and low liquidity risk, rather than rapid expansion or financial leverage.

d compliance with international standards position it for further regional market penetration.